Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 19/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 19/20 | 0.57 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12889799 | 0.95 | ITGA4 (0.54) | ITGA4ITGB1ITGB7 | |
| SCHEMBL1240168 | 0.95 | ITGA4 (0.54) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889762 | 0.91 | ITGA4 (0.48) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889801 | 0.87 | ITGA4 (0.51) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889808 | 0.87 | ITGA4 (0.51) | ITGA4ITGB1ITGB7 | |
| SCHEMBL1241181 | 0.86 | ITGA4 (0.65) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889756 | 0.85 | ITGA4 (0.51) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889813 | 0.85 | ITGA4 (0.56) | ITGA4ITGB1ITGB7 | |
| SCHEMBL12889814 | 0.84 | ITGA4 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5160231 | 0.84 | ITGA4 (0.68) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884204-B2 | such as (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(4-hydroxy-1-methyl-2-oxo-1,2-dihydro-3-quinolinyl)phenyl]propionic acid, used for the teratment of inflammatory diseases, arthritis, inflammatory bowel diseases, lupus, multiple syndrome, asthma, psoriasis, allergies, diabetes and cardiovascular diseases | AJINOMOTO CO., INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884204-B2 | such as (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(4-hydroxy-1-methyl-2-oxo-1,2-dihydro-3-quinolinyl)phenyl]propionic acid, used for the teratment of inflammatory diseases, arthritis, inflammatory bowel diseases, lupus, multiple syndrome, asthma, psoriasis, allergies, diabetes and cardiovascular diseases | AJINOMOTO CO., INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20080280909-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080280909-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-7250516-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7250516-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280909-A1 | NEW PHENYLALANINE DERIVATIVES | ITGB4, VCAM1, ITGA4 | ITGA4 3/4885ITGB1 7/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.